ClinicalTrials.gg
CompletedNCT03436836Updated May 30, 2018

Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery

An interventional study of Nalbuphine and lidocaine, bupivacaine, hyaluronidase , saline in Nalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery, sponsored by Cairo University. Completed at 2 sites in Egypt. Open to participants aged 40 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-05-30.

Sponsored by Cairo University · Not applicable, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
40 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Cataract with a site in Egypt — 4 open to participants now, 6 under way, 1 of them phase 3. Cataract · Egypt.

Enrollment
17th of 32
40 · median 45
Started
2018
with 6 others
No phase
25 of 41
1 open now
Registered
6th of 41
by date
Lead sponsor
5 of 41
Cairo University

Among the 41 studies in Cataract with a site in Egypt, this one is the 17th largest by enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2018, is one of 25 with no phase, and was the 6th registered.

Cataract

1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.

Browse Cataract studies →

Open to participants now

4 of the 41 studies in Cataract with a site in Egypt are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.

This study: 40 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Cataract with a site in Egypt, or all of them as a file.
02

Study summary

Nalbuphine has been used as an adjuvant to bupivacaine in intrathecal, epidural, caudal anesthesia and peripheral nerve blocks showing an increase in the efficacy and the duration of postoperative analgesia.The aim of this study is evaluation of the effect of nalbuphine when used as an adjuvant to a local anesthetic mixture in peribulbar block undergoing cataract surgery

Read the detailed description

44 patients (22 in each group) scheduled for elective cataract surgery using peribulbar block. Patients of Group N received local anesthetics received 6 ml of 0.5% bupivacaine 1 ml hyaluronidase (75 IU), and 4mg of Nalbuphine in 1 ml of saline (total 8 ml) and patients of Group C received 6 ml of 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and1 ml saline (total 8 ml).

Addition of nalbuphine to bupivacaine in peribulbar block is associated with reduced the time of onset of globe akinesia, increased the duration of globe akinesia and analgesia with better postoperative pain relief

03

Conditions studied

  • Nalbuphine as an Adjuvant to L. A in Peribulbar Block for Cataract Surgery

Browse trials for

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients aged 40-60 years.
  • both sex.
  • Ι\&II.
  • Patient with axial globe length below 26

Exclusion criteria

Exclusion Criteria:

  • Refusal of the patient to participate in the study.
  • Coagulation abnormalities(>1.4).
  • More than .
  • High myopia with axial length more than 26 mm.
  • Mentally retarded patients and failure of proper communication as in deafness .
  • Morbidly obese patients(>35)
  • Patients with glaucoma (increased IOP>20mmgh)
  • Patients with history of to study drugs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Group N

    group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU) and 4mg of nalbuphine in 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study

    Drug: Nalbuphine · Drug: lidocaine, bupivacaine , hyaluronidase

  • Active comparator
    Group C

    Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline

    Drug: lidocaine, bupivacaine, hyaluronidase , saline

Interventions

  • Both groups received 8 ml solution for the peribulbar block, Patients of group N was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)(16) and 4mg of nalbuphine in 1 ml normal saline. Patients of group C was received a mixture of 3 ml of 2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75 IU) and 1 ml normal saline. Nalbuphine (20mg amp.) was prepared in 0.9% sodium chloride in 5mL syringe. If the block was inadequate after 10 minutes, a 2-4 ml supplementation of local anesthetics was given by the same technique and the patient was excluded from the study. After adequate analgesia (loss of sensation to touch by a small cotton wool) and akinesia, the surgeon was allowed to start the surgery

  • Druglidocaine, bupivacaine, hyaluronidase , saline

    lidocaine, 0.5% bupivacaine, 1 ml hyaluronidase (75 IU) and 1 ml saline (total 8 ml).

  • Druglidocaine, bupivacaine , hyaluronidase

    Drug pages: Lidocaine · Bupivacaine · Hyaluronoglucosaminidase

    2% lidocaine, 4 ml of 0.5% bupivacaine with hyaluronidase (75IU)

06

What researchers measure

Primary outcomes

  1. Sensory block

    Duration of the sensory block

    Time frame: 12 hours Postoperative

Secondary outcomes

  1. Motor block

    Duration of the motor block

    Time frame: 12 hours Postoperative

  2. Sensory block onset

    Onset of the sensory block

    Time frame: 12 hours Postoperative

  3. Mean Arterial blood pressure

    Hemodynamic parameter as mean blood pressure(mmHg)

    Time frame: 24 hours postoperatively

  4. Adverse effects of the used drugs

    Adverse effects of the used drugs as nausea and vomiting

    Time frame: 24 hours postoperatively

  5. Satisfaction assessed at the end of surgical procedure by using a three-point scale

    Patient satisfaction and surgeon satisfaction

    Time frame: 6 hours Postoperative

07

Study locations

2 sites
  • Ahmed Abdalla Mohamed
    Cairo, 11451, Egypt
  • Ahmed Abdalla
    Cairo, 11451, Egypt
08

References and documents

Individual participant data

Plan to share: No — Via scholar Gate

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Feb 2018, 1 month.

Of 303 non-industry interventional studies with no phase under Cataract, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 30. This study's 1 month is below that.

Counting every sponsor, half of 493 studies reached it within 17 months; a quarter within 9 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2017
First posted
Feb 19, 2018
StartActual
Jan 14, 2018
Primary completionActual
Feb 20, 2018
CompletionActual
Feb 28, 2018
Last update
May 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03436836
Lead sponsor
Cairo University
Collaborators
Mohamed, Ahmed A., M.D., Nadia Yossif Helmy, Ahmed Elbadawy Mahmoud, Abdelhamid, Bassant Mohamed, M.D., Atef Kamel Salama, Mostafa Abdalwahab Elberry
Responsible party
Ahmed Abdalla (Assistant Professor of Anesthesia&I.C.U and Pain Clinic, Cairo University) — Principal investigator
First posted
Feb 19, 2018
Start date
Jan 14, 2018
Primary completion
Feb 20, 2018
Completion
Feb 28, 2018
Last update
May 30, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine

Start the discussion